Journal of Biomolecular Structure and Dynamics · 2020 · 38 citations · 39 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryMolecular PharmacologyPharmacophore ModelingBinding Affinity PredictionLigand BindingMolecular DockingProtein-ligand DockingStructure-activity Relationship AnalysisVirtual ScreeningBinding Free EnergyLow SolubilityMolecular Simulation AlgorithmsMolecular Simulation AnalysisPharmacokinetic Property PredictionProtein-ligand Binding Free EnergyProtein-ligand Binding Free Energy CalculationsSolubility
Estrogen receptor alpha (ERα) acts as the transcription factor and the main therapeutic target against breast cancer. One of the compounds that has been shown to act as an ERα is α-mangostin. However, it still has weaknesses due to its low solubility and low potent activity. In this study, α-mangostin was modified by substituting –OH group at C6 using benzoyl derivatives through a step by step in silico study, namely pharmacokinetic prediction (https://preadmet.bmdrc.kr/adme/), pharmacophore modeling (LigandScout 4.1), molecular docking simulation (AutoDock 4.2), molecular dynamics simulation (AMBER 16) and a binding free energy analysis using MM–PBSA method. From the computational studies, three compounds which are derived from α-mangostin (AMB-1 (−9.84 kcal/mol), AMB-2 (−6.80 kcal/mol) and AMB-10 (−12.42 kcal/mol)) have lower binding free energy than α-mangostin (−1.77 kcal/mol), as evidenced by the binding free energy calculation using the MM–PBSA method. They can then be predicted to have potent activities as ERα antagonists.Communicated by Ramaswamy H. Sarma
39
The Amber biomolecular simulation programs
David A. Case, Thomas E. Cheatham, Tom Darden et al. · Journal of Computational Chemistry · 2005 · 9.6K citations · Full text
Cancer treatment and survivorship statistics, 2016
Kimberly D. Miller, Rebecca L. Siegel, Chun Chieh Lin et al. · CA A Cancer Journal for Clinicians · 2016 · 6.2K citations · Full text